Please fill the below details

NAME:

CITY:

CONTACT NUMBER:

Indian consensus to choose Neoadjuvant treatment approach in HER2+ Early Breast Cancer

For HER2+ Early Breast Cancer, what is your criteria to consider for Neoadjuvant followed by surgery approach?

Parameters

1. Tumor Size (T)
   T1c T2 T3 T4
2. Nodal Involvement (N)
   N0 N1 N2 N3
3. Tumor Volume to Breast Ratio - High
4. Age of the Patient (Young)
5. Desire for Breast Conservation

Patients without pathological complete response after neoadjuvant treatment and surgery are now have an accessible option The World’s First TDM-1 Biosimilar

UJVIRA has passed on the benefit to more than 2500 deserving VIRAs since launch (May, 2021) improving the access for HER2+ Breast cancer patients from <5% to >20%